TY - JOUR
T1 - A comparative randomized trial of doxorubicin and cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer
AU - Buzdar, A. U.
AU - Yap, H. Y.
AU - Esparza, L.
AU - Holmes, F.
AU - Fraschini, G.
AU - Hug, V.
AU - Hortobagyi, G.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1988
Y1 - 1988
N2 - In this prospective study, two doxorubicin-containing regimens were evaluated as induction therapy, one containing etoposide (EAC) and the other fluorouracil (FAC). Following induction therapy, patients were given an alternate drug regimen consisting of vinblastine, methotrexate and either fluorouracil (VMF) or etoposide (VME), to evaluate its impact on response rate and duration of response and survival. All patients with estrogen receptor-positive tumors or unknown receptor status were also treated with tamoxifen for six to eight weeks prior to initiation of chemotherapy. Of 157 evaluable patients in the study, response to induction chemotherapy was 63% in the FAC group and 68% in the EAC arm. With alternate therapy there was improvement in response in 44% of the EAC group and in 29% of the FAC group. The durations of remissions and survival were similar between the two treatment arms. A small number of patients received regional consolidation therapy at maximum response; these patients had longer time for progression and survival.
AB - In this prospective study, two doxorubicin-containing regimens were evaluated as induction therapy, one containing etoposide (EAC) and the other fluorouracil (FAC). Following induction therapy, patients were given an alternate drug regimen consisting of vinblastine, methotrexate and either fluorouracil (VMF) or etoposide (VME), to evaluate its impact on response rate and duration of response and survival. All patients with estrogen receptor-positive tumors or unknown receptor status were also treated with tamoxifen for six to eight weeks prior to initiation of chemotherapy. Of 157 evaluable patients in the study, response to induction chemotherapy was 63% in the FAC group and 68% in the EAC arm. With alternate therapy there was improvement in response in 44% of the EAC group and in 29% of the FAC group. The durations of remissions and survival were similar between the two treatment arms. A small number of patients received regional consolidation therapy at maximum response; these patients had longer time for progression and survival.
UR - http://www.scopus.com/inward/record.url?scp=0024241903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024241903&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0024241903
SN - 0933-0453
VL - 1
SP - 48
EP - 55
JO - International Journal of Experimental and Clinical Chemotherapy
JF - International Journal of Experimental and Clinical Chemotherapy
IS - 1
ER -